Alan Fuhrman is also a member of the Board of Directors for Checkmate Pharmaceuticals and Esperion Therapeutics (where he also serves as Chair of the Audit Committee). Alan previously served on the Board of Directors and as Chair of the Audit Committee for Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019. He previously served as the Chief Financial Officer of Amplyx Pharmaceuticals until his retirement in June 2020. Prior to joining Amplyx, he served as the Chief Financial Officer of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company that merged with Synlogic in 2017. Alan also previously served as Chief Financial Officer of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Earlier in his career, Alan practiced as a certified public accountant with Coopers & Lybrand. Alan received a B.S. in both Business Administration and Agricultural Economics from Montana State University.